Madopar is an anti-Parkinsonian agent. Levodopa is the metabolic precursor of dopamine. The latter is severely depleted in the striatum, pallidum and substantia nigra of Parkinsonian patients and it is considered that administration of levodopa raises the level of available dopamine in these centers. However, the conversion of levodopa into dopamine by the enzyme dopa decarboxylase also takes place in extracerebral tissues. As a result, the full therapeutic effect may not be obtained and side-effects occur.
Administration of a peripheral decarboxylase inhibitor, which blocks the extracerebral decarboxylation of levodopa, in conjunction with levodopa has significant advantages; these include reduced gastrointestinal side-effects, a more rapid response at the initiation of therapy and a simpler dosage regimen. Madopar is a combination of levodopa and benserazide in the ratio 4:1 which in clinical trials is the most pleasing.
- abnormal involuntary jerking movements of the body. These are usually caused if your dose is too high and will lessen or disappear when your dose is reduced
- mental changes including paranoia, depression, mania, agitation and hallucinations (seeing, feeling or hearing things that are not there)
- nausea and vomiting
- loss of appetite
- weight gain
- skin rash or itching
- confusion, tiredness, sleeplessness, or sudden onset of sleep episodes
- poor muscle tone, hiccups
- water retention, cramps
- changes in sex drive or hypersexuality
- uncontrollable excessive shopping or spending
- loss of taste
- frequent infections such as fever, severe chills